Defunct Company
Total Trials
23
As Lead Sponsor
20
As Collaborator
3
Total Enrollment
926
NCT00004213
3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: May 31, 1998
Completion: Jan 31, 2008
NCT00004216
VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy
Start: Aug 31, 1999
NCT00006218
3-AP in Treating Patients With Advanced Cancer
Start: May 31, 2000
NCT00006254
VNP20009 in Treating Patients With Advanced Solid Tumors
NCT00016874
3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
Start: Dec 31, 2000
NCT00024323
Combination Chemotherapy in Treating Patients With Advanced Cancer
Start: Mar 31, 2001
Completion: Jun 30, 2003
NCT00025129
VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas
Completion: May 31, 2004
NCT00049686
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
Start: Apr 30, 2002
NCT00049699
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
Start: Oct 31, 2002
NCT00054015
3-AP in Treating Patients With Advanced Prostate Cancer
Phase: Phase 2
Start: Dec 31, 2002
NCT00064051
3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
Start: Jan 31, 2003
Completion: Aug 31, 2008
NCT00064064
3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
NCT00064090
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
Start: Mar 31, 2003
NCT00070538
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
Start: Jun 30, 2003
NCT00098436
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias
Start: Sep 30, 2004
NCT00112554
Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia
Phase: Phase 3
Start: Mar 31, 2005
Completion: Mar 31, 2008
NCT00304005
VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders
Phase: Phase 1/2
Start: Jul 31, 2005
NCT00282022
VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer
Start: Sep 30, 2005
Completion: Not specified
NCT00083187
VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
Start: Nov 30, 2005
NCT00354276
VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia
Start: May 31, 2006
NCT00516282
VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma
Role: Collaborator
Start: Aug 31, 2007
Completion: Oct 31, 2009
NCT00521859
Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies
Completion: Dec 31, 2010
NCT00655395
Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine
Start: Mar 31, 2008
Completion: Oct 31, 2010